Last reviewed · How we verify
iHSCs treatment group
At a glance
| Generic name | iHSCs treatment group |
|---|---|
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iHSCs treatment group CI brief — competitive landscape report
- iHSCs treatment group updates RSS · CI watch RSS
- Allife Medical Science and Technology Co., Ltd. portfolio CI